文献速递脑血管病

归因于大血管或小血管疾病的卒中患者的心房颤动:STROKE AF 随机临床试验的3年结果

Atrial Fibrillation In Patients With Stroke Attributed to Large- or Small-Vessel Disease: 3-Year Results From the STROKE AF Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2023-01-01

STROKE AF 试验在美国33个中心随机分配492例归因于大动脉粥样硬化性疾病或小血管闭塞性疾病的缺血性卒中患者,比较植入式心脏监测器与部位常规护理。3年时心房颤动检出率在植入式心脏监测器组为21.7%(46例),对照组为2.4%(5例),风险比为10.0(95%CI 4.0-25.2;P<.001)。

要点

  • 归因于大动脉粥样硬化性疾病或小血管闭塞性疾病的卒中患者,植入式心脏监测器组3年心房颤动检出率为21.7%,对照组为2.4%。
  • 风险比为10.0(95%CI 4.0-25.2;P<.001),心房颤动检出随时间增加。
  • 大多数心房颤动发作无法通过标准医学监测方法可靠检出,1年阴性监测不能保证未来2年不出现心房颤动。

核心结论

  • 归因于大动脉粥样硬化性疾病或小血管闭塞性疾病的缺血性卒中患者,心房颤动风险随时间增加,且大多数心房颤动发作无法通过标准医学监测方法可靠检出。
  • 1年阴性监测不应让临床医生确信发生过卒中的患者在未来2年内不会出现心房颤动。

研究设计与样本

  • 多中心、随机(1:1)临床试验,在美国33个中心进行,入组时间为2016年4月至2019年7月,3年随访至2022年7月。
  • 共入组496例患者,492例随机分组并纳入分析,4例被排除。
  • 纳入标准:年龄60岁及以上,或年龄50至59岁且至少具有1项额外卒中危险因素,并且在植入式心脏监测器插入前10天内发生归因于大动脉粥样硬化性疾病或小血管闭塞性疾病的索引缺血性卒中。
  • 干预为植入式心脏监测器监测对比部位常规护理。
  • 预先设定的长期结局为研究随访期间(最长3年)的心房颤动检出,心房颤动定义为持续超过30秒的发作,由专家委员会裁定。

主要发现

  • 492例随机患者中,中位年龄(IQR)为66(60-74)岁,男性307例(62.4%),女性185例(37.6%),314例(63.8%)完成3年随访。
  • 3年时心房颤动发生率在植入式心脏监测器组为21.7%(46例),对照组为2.4%(5例),风险比为10.0(95%CI 4.0-25.2;P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The STROKE AF study found that in patients with prior ischemic stroke attributed to large-artery atherosclerotic disease (LAD) or small-vessel occlusive disease (SVD), 12% developed AF over 1 year when monitored with an insertable cardiac monitor (ICM). The occurrence over subsequent years is unknown. OBJECTIVES: To compare the rates of AF detection through 3 years of follow-up between an ICM vs site-specific usual care in patients with prior ischemic stroke attributed to LAD or SVD. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized (1:1) clinical trial took place at 33 sites in the US with enrollment between April 2016 and July 2019 and 3-year follow-up through July 2022. Eligible patients were aged 60 years or older, or aged 50 to 59 years with at least 1 additional stroke risk factor and had an index ischemic stroke attributed to LAD or SVD within 10 days prior to ICM insertion. Of the 496 patients enrolled, 492 were randomized and 4 were excluded. INTERVENTIONS: ICM monitoring vs site-specific usual care. MAIN OUTCOMES AND MEASURES: The prespecified long-term outcome of the trial was AF detection through study follow-up (up to 3 years). AF was defined as an episode lasting more than 30 seconds, adjudicated by an expert committee. RESULTS: In total, 492 patients were randomized and included in the analyses (median [IQR] age, 66 [60-74] years; 307 men [62.4%] and 185 women [37.6%]), of whom 314 completed 3-year follow-up (63.8%). The incidence rate of AF at 3 years was 21.7% (46 patients) in the ICM group vs 2.4% (5 patients) in the control group (hazard ratio, 10.0; 95% CI, 4.0-25.2; P < .001). CONCLUSIONS AND RELEVANCE: Patients with ischemic stroke attributed to LAD or SVD face an increasing risk of AF over time and most of the AF occurrences are not reliably detected by standard medical monitoring methods. One year of negative monitoring should not reassure clinicians that patients who have experienced stroke will not develop AF over the next 2 years. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02700945.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Bernstein RA, Kamel H, Granger CB, et al. Atrial Fibrillation In Patients With Stroke Attributed to Large- or Small-Vessel Disease: 3-Year Results From the STROKE AF Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37902733. doi:10.1001/jamaneurol.2023.3931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。